Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan
BACKGROUND: Pakistan ranks fourth globally in terms of high drug-resistant TB (DR-TB) burden, with approximately one-third of cases resistant to fluoroquinolones. Bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM/BPaL) offers an opportunity for most DR-TB patients to benefit from a shorter,...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-11-01
|
Series: | IJTLD Open |
Subjects: | |
Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000011/art00006 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|